Glucocorticoid treatment and cardiovascular disease
Open Access
- 1 August 2004
- Vol. 90 (8), 829-830
- https://doi.org/10.1136/hrt.2003.031492
Abstract
The propensity of glucocorticoids to produce hyperglycaemia, hypertension, dyslipidaemia, and central obesity has long been a cause for concern among physicians regarding possible adverse cardiovascular events. Should heart failure be added to this list of concerns?Keywords
This publication has 21 references indexed in Scilit:
- Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control studyHeart, 2004
- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 2003
- Inflammation in atherosclerosisNature, 2002
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- CORTISOL AND HYPERTENSIONClinical and Experimental Pharmacology and Physiology, 1998
- Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty.JCI Insight, 1994
- Role of inflammatory responses in initiation of atherosclerosis: effects of anti-inflammatory drugs on cuff-induced leukocyte accumulation and intimal thickening of rabbit carotid arteryAtherosclerosis, 1991
- Anti-inflammatory drugs in experimental atherosclerosisAtherosclerosis, 1989
- Protective Action of Methylprednisolone on the Myocardium during Experimental Myocardial Ischemia in the CatCirculation Research, 1974
- Reduction of Experimental Myocardial Infarct Size by Corticosteroid AdministrationJCI Insight, 1973